glp 1 agonist full form Glucagon-like peptide-1 GLP1-GIP receptor co-agonists: a promising
Description
& Seino, Y
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial
Observational studies indicate a potential reduced risk of developing dementia, including Alzheimers, in patients using GLP-1 agonists [16, 23]
Several real-world studies based on administrative data and pharmacy reports have demonstrated that reduced adherence to antidiabetic therapy is associated not only with poorer glycemic control but also with a significant increase in overall mortality and hospitalizations for all causes [70, 71]
Prescribing information (Amneal Pharmaceuticals, 2025)
JAMA Intern Med 2016;176:1474-81.ArticlePubMed 38
